Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06414954 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
A Phase 2 study of Myasthenia Gravis and Myasthenia Gravis, MuSK, sponsored by NMD Pharma A/S.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 20
- Study locations
NCT06414954: Recruiting Phase 2 study of Myasthenia Gravis and Myasthenia Gravis, MuSK, sponsored by NMD Pharma A/S.
NCT06414954 is a Phase 2 study of Myasthenia Gravis and Myasthenia Gravis, MuSK that is actively recruiting participants, run by NMD Pharma A/S. The registered enrollment target is 84 participants, below the 189-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06414954, a Phase 2 study of Myasthenia Gravis and Myasthenia Gravis, MuSK, is actively recruiting participants, sponsored by NMD Pharma A/S.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.
Primary Outcome
Scale goes from 0-39 and higher score indicates worse symptomatology
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NMD670
Study Locations (20)
Other
- UZ Leuven - Leuven
- Aarhus University Hospital - Aarhus
- Rigshospitalet University of Copenhagen - Copenhagen
- Centre de référence des maladies neuromusculaires AOC-CHU de Bordeaux - Hôpital Pellegrin - Bordeaux
- Centre de Référence des Maladies Neuromusculaires et de la SLA - Marseille
- Centre Hospitalier Universitaire de Nantes - Hôtel Dieu Centre de Référence des Maladies Neuromusculaires Rares - - Nantes
- CHU de Nice - Nice
- Unité de Recherche Clinique NeuroSciences - Nice
- JSC Curatio - Tbilisi
California
- Profound Research LLC - Carlsbad
- University of California Irvine Medical Center - Irvine
Florida
- SFM Clinical Research, LLC - Boca Raton
- Neuromuscular Research Division | University of South Florida - Tampa
Colorado
- University of Colorado Neuromuscular Division - Aurora
Georgia
- Augusta University, Neuroscience Center - Augusta
Missouri
- NextGen Precision Health - Columbia
North Carolina
- The University of North Carolina at Chapel Hill - Chapel Hill
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2024-05-16 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
What NCT06414954 shows while recruiting
NCT06414954 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 189-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (56% lower).
The record links to 2 conditions, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06414954 names 20 study sites across 10 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06414954 about?
NCT06414954 is a clinical study titled "Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis". This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.
What is the current status of trial NCT06414954?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2024-05-16. Estimated completion is 2026-05.
What conditions does trial NCT06414954 study?
This clinical trial studies the following conditions: Myasthenia Gravis, Myasthenia Gravis, MuSK.
What interventions are being tested in trial NCT06414954?
The interventions under investigation include: Placebo (DRUG), NMD670 (DRUG).
Who is sponsoring clinical trial NCT06414954?
This trial is sponsored by NMD Pharma A/S, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06414954 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06414954's enrollment target sits among peer trials
84 18th of 32 higher than 15 of 32 other Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
RECRUITING · Phase 2
-
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
COMPLETED · Phase 2
-
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
COMPLETED · Phase 2
-
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI